Patents by Inventor Christoffer Sondergaard

Christoffer Sondergaard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antisense Oligonucleotides Targeting ATXN3
    Publication number: 20230060373
    Abstract: The present invention relates to antisense LNA oligonucleotides (oligomers) complementary to ATXN3 pre-mRNA sequences, which are capable of inhibiting the expression of ATXN3 protein. Inhibition of ATXN3 expression is beneficial for the treatment of spinocerebellar ataxia.
    Type: Application
    Filed: December 2, 2021
    Publication date: March 2, 2023
    Inventors: Heidi Rye Hudlebusch, Alexander Herbert Stephan, Lykke Pedersen, Christoffer Sondergaard, Erik Funder
  • Antisense Oligonucleotides Targeting ATXN3
    Publication number: 20230054720
    Abstract: The present invention relates to antisense LNA oligonucleotides (oligomers) complementary to ATXN3 pre-mRNA sequences, which are capable of inhibiting the expression of ATXN3 protein.
    Type: Application
    Filed: December 2, 2021
    Publication date: February 23, 2023
    Inventors: Heidi Rye Hudlebusch, Lykke Pedersen, Erik Funder, Lukasz Kielpinski, Christoffer Sondergaard, Alexander Herbert Stephan, Mads Manso
  • Antisense oligonucleotides targeting ATXN3
    Patent number: 11542501
    Abstract: The present invention relates to antisense LNA oligonucleotides (oligomers) complementary to ATXN3 pre-mRNA sequences, which are capable of inhibiting the expression of ATXN3 protein. Inhibition of ATXN3 expression is beneficial for the treatment of spinocerebellar ataxia.
    Type: Grant
    Filed: June 5, 2020
    Date of Patent: January 3, 2023
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Marianne Ravn Møller, Heidi Rye Hudlebusch, Lykke Pedersen, Erik Daa Funder, Christoffer Sondergaard, Jette Dam Hedegaard, Alexander Herbert Stephan, Peter Hagedorn
  • Antisense Oligonucleotides Targeting ATXN3
    Publication number: 20220177883
    Abstract: The present invention relates to antisense LNA oligonucleotides (oligomers) complementary to ATXN3 pre-mRNA sequences, which are capable of inhibiting the expression of ATXN3 protein. Inhibition of ATXN3 expression is beneficial for the treatment of spinocerebellar ataxia.
    Type: Application
    Filed: December 2, 2021
    Publication date: June 9, 2022
    Inventors: Heidi Rye Hudlebusch, Lykke Pedersen, Erik Funder, Lukasz Kielpinski, Christoffer Sondergaard, Alexander Herbert Stephan
  • OLIGONUCLEOTIDES FOR MODULATING SCN9A EXPRESSION
    Publication number: 20210238608
    Abstract: The present invention relates to oligonucleotides (oligomers) that are complementary to voltage-gated sodium ion channel encoding nucleic acids, such as SCN9A, which encodes the voltage-gated sodium channel Nav1.7. The oligonucleotides of the invention are capable of inhibiting the expression of voltage-gated sodium ion channels, such as Nav1.7, and are useful in the prevention or the treatment of pain.
    Type: Application
    Filed: December 22, 2020
    Publication date: August 5, 2021
    Inventors: Lykke PEDERSEN, Søren RASMUSSEN, Gianluigi LICHINCHI, Christoffer SONDERGAARD
  • ANTISENSE OLIGONUCLEOTIDES TARGETING ATXN3
    Publication number: 20200385727
    Abstract: The present invention relates to antisense LNA oligonucleotides (oligomers) complementary to ATXN3 pre-mRNA sequences, which are capable of inhibiting the expression of ATXN3 protein. Inhibition of ATXN3 expression is beneficial for the treatment of spinocerebellar ataxia.
    Type: Application
    Filed: June 5, 2020
    Publication date: December 10, 2020
    Inventors: Marianne Ravn Møller, Heidi Rye Hudlebusch, Lykke Pedersen, Erik Daa Funder, Christoffer Sondergaard, Jette Dam Hedegaard, Alexander Herbert Stephan